KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Capital Expenditures (2016 - 2025)

Amgen (AMGN) has 17 years of Capital Expenditures data on record, last reported at $642.0 million in Q4 2025.

  • For Q4 2025, Capital Expenditures rose 73.05% year-over-year to $642.0 million; the TTM value through Dec 2025 reached $1.9 billion, up 69.53%, while the annual FY2025 figure was $1.9 billion, 69.53% up from the prior year.
  • Capital Expenditures reached $642.0 million in Q4 2025 per AMGN's latest filing, up from $436.0 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $642.0 million in Q4 2025 and bottomed at $160.0 million in Q3 2022.
  • Average Capital Expenditures over 5 years is $294.1 million, with a median of $253.0 million recorded in 2023.
  • Peak YoY movement for Capital Expenditures: crashed 33.88% in 2022, then soared 81.05% in 2023.
  • A 5-year view of Capital Expenditures shows it stood at $287.0 million in 2021, then grew by 18.47% to $340.0 million in 2022, then decreased by 26.76% to $249.0 million in 2023, then skyrocketed by 49.0% to $371.0 million in 2024, then surged by 73.05% to $642.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $642.0 million in Q4 2025, $436.0 million in Q3 2025, and $369.0 million in Q2 2025.